An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
|Articles|April 29, 2003
Age at baseline most important factor affecting BPH progression in treatedpatients
Chicago-A higher age at baseline predicted increased rate of progressionin all three treatment arms of the Medical Therapy of Prostate Symptoms(MTOPS) trial, according to a secondary analysis of data presented at theAUA meeting yesterday.
Advertisement
Advertisement
Related to this article
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
4
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
5